The ENHANCE-AF clinical trial to evaluate an atrial fibrillation shared decision-making pathway: Rationale and study design
Tina Baykaner,Krishna Pundi,Bryant Lin,Ying Lu,Katie DeSutter,Karma Lhamo,Gotzone Garay,Julio C Nunes,Daniel P Morin,Samuel F Sears,Mina K Chung,Michael K Paasche-Orlow,Lee M Sanders,Thomas Jared Bunch,Mellanie True Hills,Kenneth W Mahaffey,Randall S Stafford,Paul J Wang,Julio C. Nunes,Daniel P. Morin,Samuel F. Sears,Mina K. Chung,Michael K. Paasche-Orlow,Lee M. Sanders,Kenneth W. Mahaffey,Randall S. Stafford,Paul J. Wang
DOI: https://doi.org/10.1016/j.ahj.2022.01.013
IF: 5.099
2022-05-01
American Heart Journal
Abstract:INTRODUCTION: Shared decision making (SDM) may result in treatment plans that best reflect the goals and wishes of patients, increasing patient satisfaction with the decision-making process. There is a knowledge gap to support the use of decision aids in SDM for anticoagulation therapy in patients with atrial fibrillation (AF). We describe the development and testing of a new decision aid, including a multicenter, randomized, controlled, 2-arm, open-label ENHANCE-AF clinical trial (Engaging Patients to Help Achieve Increased Patient Choice and Engagement for AF Stroke Prevention) to evaluate its effectiveness in 1,200 participants.METHODS: Participants will be randomized to either usual care or to a SDM pathway incorporating a digital tool designed to simplify the complex concepts surrounding AF in conjunction with a clinician tool and a non-clinician navigator to guide the participants through each step of the tool. The participant-determined primary outcome for this study is the Decisional Conflict Scale, measured at 1 month after the index visit during which a decision was made regarding anticoagulation use. Secondary outcomes at both 1 and 6 months will include other decision making related scales as well as participant and clinician satisfaction, oral anticoagulation adherence, and a composite rate of major bleeding, death, stroke, or transient ischemic attack. The study will be conducted at four sites selected for their ability to enroll participants of varying racial and ethnic backgrounds, health literacy, and language skills. Participants will be followed in the study for 6 months.CONCLUSIONS: The results of the ENHANCE-AF trial will determine whether a decision aid facilitates high quality shared decision making in anticoagulation discussions for stroke reduction in AF. An improved shared decision-making experience may allow patients to make decisions better aligned with their personal values and preferences, while improving overall AF care.
cardiac & cardiovascular systems